Type 1 Diabetes | Treatment Algorithms: Claims Data Analysis | US | 2024
Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulins continue to dominate the T1D market; they are the primary treatment option for disease management, with long-acting and rapid-acting insulins being the patient-share leaders in the United States. The choice of branded insulin, choice of regimen, and order in which brands and/or regimens are attempted vary. In addition, biosimilar / interchangeable insulins have added a layer of complexity to the T1D therapy market. The increasing use of insulin pumps is also playing a role in the evolving T1D market.
QUESTIONS ANSWERED
- What patient shares do key therapies garner by line of therapy in newly diagnosed T1D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T1D patients?
- How have ultra-rapid insulins been integrated into the treatment algorithm, and what is the source of business?
- What percentage of T1D patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of T1D patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States.
Key drugs: Lyumjev, Lantus, Levemir, Toujeo, Apidra, NovoLog, Fiasp, Humalog, Admelog, Basaglar.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
